The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2022 | Healthcare decision-making in patients with DLBCL treated with CAR-T vs. non-CAR-T therapies
In this video, Lorna Warwick, BA, Lymphoma Coalition, Toronto, Canada, shares some insights into healthcare decision-making in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) being treated with chimeric antigen receptor T-cell (CAR-T) therapy versus non-CAR-T therapies. Using data from a global patient survey, Ms Warwick explains a study that analyzed the data to see how involved patients felt in their healthcare decision-making process in a CAR-T setting versus other treatments. Ms Warwick also highlights the importance of ensuring that patients undergoing CAR-T therapy feel fully informed and educated, and that information gaps should be filled in order to help give patients the best information before making a decision. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
